{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:24:52Z","timestamp":1792621492900,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T00:00:00Z","timestamp":1662854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T00:00:00Z","timestamp":1662854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1147370"],"award-info":[{"award-number":["APP1147370"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There is an unmet need for treatments for knee osteoarthritis (OA). Effusion-synovitis is a common inflammatory phenotype of knee OA and predicts knee pain and structural degradation. Anti-inflammatory therapies, such as diacerein, may be effective for this phenotype. While diacerein is recommended for alleviating pain in OA patients, evidence for its effectiveness is inconsistent, possibly because studies have not targeted patients with an inflammatory phenotype. Therefore, we will conduct a multi-centre, randomised, placebo-controlled double-blind trial to determine the effect of diacerein on changes in knee pain and effusion-synovitis over 24 weeks in patients with knee OA and magnetic resonance imaging (MRI)-defined effusion-synovitis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We will recruit 260 patients with clinical knee OA, significant knee pain, and MRI-detected effusion-synovitis in Hobart, Melbourne, Adelaide, and Perth, Australia. They will be randomly allocated to receive either diacerein (50mg twice daily) or identical placebo for 24 weeks. MRI of the study knee will be performed at screening and after 24 weeks of intervention. The primary outcome is improvement in knee pain at 24 weeks as assessed by a 100-mm visual analogue scale (VAS). Secondary outcomes include improvement in volumetric (ml) and semi-quantitative (Whole-Organ Magnetic Resonance Imaging Score, 0\u20133) measurements of effusion-synovitis using MRI over 24 weeks, and improvement in knee pain (VAS) at 4, 8, 12, 16, and 20 weeks. Intention-to-treat analyses of primary and secondary outcomes will be performed as the primary analyses. Per protocol analyses will be performed as the secondary analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This study will provide high-quality evidence to determine whether diacerein improves pain, changes disease trajectory, and slows disease progression in OA patients with effusion-synovitis. If diacerein proves effective, this has the potential to significantly benefit the substantial proportion (up to 60%) of knee OA patients with an inflammatory phenotype.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Australian and New Zealand Clinical Trial Registry <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.anzctr.org.au\/Default.aspx\">ACTRN12618001656224<\/jats:ext-link>. Registered on 08 October 2018.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06715-w","type":"journal-article","created":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T16:02:34Z","timestamp":1662912154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Study protocol for a randomised controlled trial of diacerein versus placebo to treat knee osteoarthritis with effusion-synovitis (DICKENS)"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6481-704X","authenticated-orcid":false,"given":"Guoqi","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia M.","family":"Cicuttini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita E.","family":"Wluka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benny","family":"Antony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"de Graaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Winzenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Buttigieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Aitken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,11]]},"reference":[{"issue":"10182","key":"6715_CR1","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0140-6736(19)30417-9","volume":"393","author":"DJ Hunter","year":"2019","unstructured":"Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745\u201359.","journal-title":"Lancet"},{"issue":"5","key":"6715_CR2","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/1529-0131(200010)13:5<312::AID-ANR11>3.0.CO;2-L","volume":"13","author":"D Tallon","year":"2000","unstructured":"Tallon D, Chard J, Dieppe P. Exploring the priorities of patients with osteoarthritis of the knee. Arthritis Care Res. 2000;13(5):312\u20139.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"6715_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1517\/14728214.2011.576670","volume":"16","author":"GL Matthews","year":"2011","unstructured":"Matthews GL, Hunter DJ. Emerging drugs for osteoarthritis. Expert Opin Emerg Drugs. 2011;16(3):479\u201391.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"3","key":"6715_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2217\/ijr.13.19","volume":"8","author":"G Jones","year":"2013","unstructured":"Jones G. Sources of pain in osteoarthritis: implications for therapy. Int J Clin Rheumatol. 2013;8(3):335\u201343.","journal-title":"Int J Clin Rheumatol"},{"issue":"12","key":"6715_CR5","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.joca.2018.08.002","volume":"26","author":"F Pan","year":"2018","unstructured":"Pan F, et al. Predictors of pain severity trajectory in older adults: a 10.7-year follow-up study. Osteoarthr Cartil. 2018;26(12):1619\u201326.","journal-title":"Osteoarthr Cartil"},{"issue":"2","key":"6715_CR6","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/rheumatology\/key299","volume":"58","author":"F Pan","year":"2019","unstructured":"Pan F, et al. Differentiating knee pain phenotypes in older adults: a prospective cohort study. Rheumatology (Oxford). 2019;58(2):274\u201383.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"6715_CR7","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1016\/j.joca.2017.08.009","volume":"25","author":"LA Deveza","year":"2017","unstructured":"Deveza LA, et al. Knee osteoarthritis phenotypes and their relevance for outcomes: a systematic review. Osteoarthr Cartil. 2017;25(12):1926\u201341.","journal-title":"Osteoarthr Cartil"},{"issue":"8","key":"6715_CR8","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.joca.2017.02.804","volume":"25","author":"X Wang","year":"2017","unstructured":"Wang X, et al. Knee effusion-synovitis volume measurement and effects of vitamin D supplementation in patients with knee osteoarthritis. Osteoarthr Cartil. 2017;25(8):1304\u201312.","journal-title":"Osteoarthr Cartil"},{"issue":"2","key":"6715_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.bone.2012.02.012","volume":"51","author":"CR Scanzello","year":"2012","unstructured":"Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone. 2012;51(2):249\u201357.","journal-title":"Bone"},{"issue":"1","key":"6715_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3899\/jrheum.150355","volume":"43","author":"X Wang","year":"2016","unstructured":"Wang X, et al. Cross-sectional and Longitudinal Associations between Knee Joint Effusion Synovitis and Knee Pain in Older Adults. J Rheumatol. 2016;43(1):121\u201330.","journal-title":"J Rheumatol"},{"issue":"3","key":"6715_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1136\/annrheumdis-2014-206676","volume":"75","author":"X Wang","year":"2016","unstructured":"Wang X, et al. Association between MRI-detected knee joint regional effusion-synovitis and structural changes in older adults: a cohort study. Ann Rheum Dis. 2016;75(3):519\u201325.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"6715_CR12","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/ard.2008.099564","volume":"69","author":"PG Conaghan","year":"2010","unstructured":"Conaghan PG, et al. Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study. Ann Rheum Dis. 2010;69(4):644\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"6715_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40264-015-0266-z","volume":"38","author":"E Panova","year":"2015","unstructured":"Panova E, Jones G. Benefit-risk assessment of diacerein in the treatment of osteoarthritis. Drug Saf. 2015;38(3):245\u201352.","journal-title":"Drug Saf"},{"issue":"3","key":"6715_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1080\/19420862.2015.1026501","volume":"7","author":"SE Lacy","year":"2015","unstructured":"Lacy SE, et al. Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta. MAbs. 2015;7(3):605\u201319.","journal-title":"MAbs"},{"issue":"22","key":"6715_CR15","doi-asserted-by":"publisher","first-page":"8749","DOI":"10.1073\/pnas.83.22.8749","volume":"83","author":"ER Pettipher","year":"1986","unstructured":"Pettipher ER, Higgs GA, Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci U S A. 1986;83(22):8749\u201353.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"6715_CR16","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1002\/art.30360","volume":"63","author":"M Attur","year":"2011","unstructured":"Attur M, et al. Increased interleukin-1beta gene expression in peripheral blood leukocytes is associated with increased pain and predicts risk for progression of symptomatic knee osteoarthritis. Arthritis Rheum. 2011;63(7):1908\u201317.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"6715_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/joca.1998.0199","volume":"7","author":"N Felisaz","year":"1999","unstructured":"Felisaz N, et al. Stimulating effect of diacerein on TGF-beta1 and beta2 expression in articular chondrocytes cultured with and without interleukin-1. Osteoarthr Cartil. 1999;7(3):255\u201364.","journal-title":"Osteoarthr Cartil"},{"issue":"3","key":"6715_CR18","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/1529-0131(199904)42:3<545::AID-ANR20>3.0.CO;2-4","volume":"42","author":"GN Smith Jr","year":"1999","unstructured":"Smith GN Jr, et al. Diacerhein treatment reduces the severity of osteoarthritis in the canine cruciate-deficiency model of osteoarthritis. Arthritis Rheum. 1999;42(3):545\u201354.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"6715_CR19","doi-asserted-by":"publisher","first-page":"R65","DOI":"10.1186\/ar1028","volume":"6","author":"E Douni","year":"2004","unstructured":"Douni E, et al. Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols. Arthritis Res Ther. 2004;6(1):R65\u201372.","journal-title":"Arthritis Res Ther"},{"key":"6715_CR20","doi-asserted-by":"publisher","first-page":"CD005117","DOI":"10.1002\/14651858.CD005117.pub3","volume":"2","author":"TS Fidelix","year":"2014","unstructured":"Fidelix TS, et al. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014;2:CD005117. https:\/\/doi.org\/10.1002\/14651858.CD005117.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"6715_CR21","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.joca.2003.09.008","volume":"12 Suppl A","author":"MC Hochberg","year":"2004","unstructured":"Hochberg MC, Lethbridge-Cejku M, Tobin JD. Bone mineral density and osteoarthritis: data from the Baltimore Longitudinal Study of Aging. Osteoarthr Cartil. 2004;12 Suppl A:S45\u20138.","journal-title":"Osteoarthr Cartil"},{"issue":"11","key":"6715_CR22","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.joca.2019.06.011","volume":"27","author":"RR Bannuru","year":"2019","unstructured":"Bannuru RR, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr Cartil. 2019;27(11):1578\u201389.","journal-title":"Osteoarthr Cartil"},{"issue":"2","key":"6715_CR23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/art.41142","volume":"72","author":"SL Kolasinski","year":"2020","unstructured":"Kolasinski SL, et al. 2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheum. 2020;72(2):220\u201333.","journal-title":"Arthritis Rheum"},{"key":"6715_CR24","unstructured":"European Medicines Agency (EMA\u2019s) Pharmacovigilance and Risk Assessment Committee (PRAC), Assessment report for diacerein containing medicinal products. 28 Aug 2014. Procedure under Article 31 of Directive 2001\/83\/EC resulting from pharmacovigilance data. Procedure number: EMEA\/H\/A-31\/1349. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/diacerein-article-31-referral-prac-assessment-report_en.pdf Accessed 15 June 2022."},{"issue":"2","key":"6715_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40266-016-0347-4","volume":"33","author":"K Pavelka","year":"2016","unstructured":"Pavelka K, et al. Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs Aging. 2016;33(2):75\u201385.","journal-title":"Drugs Aging"},{"issue":"3","key":"6715_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med"},{"issue":"5","key":"6715_CR27","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.joca.2015.03.005","volume":"23","author":"TE McAlindon","year":"2015","unstructured":"McAlindon TE, et al. OARSI Clinical Trials Recommendations: Design, conduct, and reporting of clinical trials for knee osteoarthritis. Osteoarthr Cartil. 2015;23(5):747\u201360.","journal-title":"Osteoarthr Cartil"},{"issue":"1","key":"6715_CR28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13075-020-2143-0","volume":"22","author":"WE van Spil","year":"2020","unstructured":"van Spil WE, et al. A consensus-based framework for conducting and reporting osteoarthritis phenotype research. Arthritis Res Ther. 2020;22(1):54.","journal-title":"Arthritis Res Ther"},{"key":"6715_CR29","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.","journal-title":"BMJ"},{"issue":"3","key":"6715_CR30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/jama.2021.9941","volume":"326","author":"AM Orkin","year":"2021","unstructured":"Orkin AM, et al. Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement. JAMA. 2021;326(3):257\u201365.","journal-title":"JAMA"},{"key":"6715_CR31","volume-title":"COVID-19: Guidance on clinical trials for institutions, HRECs, researchers and sponsors","author":"Australian Government Department of Health","year":"2020","unstructured":"Australian Government Department of Health. COVID-19: Guidance on clinical trials for institutions, HRECs, researchers and sponsors; 2020. https:\/\/www1.health.gov.au\/internet\/main\/publishing.nsf\/Content\/EE207D978A44E4B8CA257FA90081B212\/$File\/COVID-19%20Guidance%20on%20clinical%20trials%20for%20institutions,%20HRECs,%20researchers%20and%20sponsors.pdf Accessed 15 June 2022"},{"issue":"15","key":"6715_CR32","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/jama.2020.2938","volume":"323","author":"G Cai","year":"2020","unstructured":"Cai G, et al. Effect of Intravenous Zoledronic Acid on Tibiofemoral Cartilage Volume Among Patients With Knee Osteoarthritis With Bone Marrow Lesions: A Randomized Clinical Trial. JAMA. 2020;323(15):1456\u201366.","journal-title":"JAMA"},{"issue":"8","key":"6715_CR33","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/art.1780290816","volume":"29","author":"R Altman","year":"1986","unstructured":"Altman R, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29(8):1039\u201349.","journal-title":"Arthritis Rheum"},{"key":"6715_CR34","first-page":"3","volume":"3 Suppl A","author":"RD Altman","year":"1995","unstructured":"Altman RD, et al. Atlas of individual radiographic features in osteoarthritis. Osteoarthr Cartil. 1995;3 Suppl A:3\u201370 PMID: 8581752.","journal-title":"Osteoarthr Cartil"},{"key":"6715_CR35","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1016\/j.joca.2006.11.009","volume":"15 Suppl A","author":"RD Altman","year":"2007","unstructured":"Altman RD, Gold GE. Atlas of individual radiographic features in osteoarthritis, revised. Osteoarthr Cartil. 2007;15 Suppl A:A1\u201356. https:\/\/doi.org\/10.1016\/j.joca.2006.11.009.","journal-title":"Osteoarthr Cartil"},{"issue":"10","key":"6715_CR36","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1002\/1529-0131(200010)43:10<2339::AID-ANR23>3.0.CO;2-P","volume":"43","author":"JP Pelletier","year":"2000","unstructured":"Pelletier JP, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000;43(10):2339\u201348.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"6715_CR37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00256-008-0570-0","volume":"38","author":"S Fenn","year":"2009","unstructured":"Fenn S, Datir A, Saifuddin A. Synovial recesses of the knee: MR imaging review of anatomical and pathological features. Skelet Radiol. 2009;38(4):317\u201328.","journal-title":"Skelet Radiol"},{"issue":"3","key":"6715_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.joca.2003.11.003","volume":"12","author":"CG Peterfy","year":"2004","unstructured":"Peterfy CG, et al. Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis. Osteoarthr Cartil. 2004;12(3):177\u201390.","journal-title":"Osteoarthr Cartil"},{"issue":"11","key":"6715_CR39","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1002\/acr.21747","volume":"64","author":"F Tubach","year":"2012","unstructured":"Tubach F, et al. Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. Arthritis Care Res. 2012;64(11):1699\u2013707.","journal-title":"Arthritis Care Res"},{"issue":"12","key":"6715_CR40","first-page":"1833","volume":"15","author":"N Bellamy","year":"1988","unstructured":"Bellamy N, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833\u201340 PMID: 3068365.","journal-title":"J Rheumatol"},{"issue":"5","key":"6715_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.joca.2004.02.001","volume":"12","author":"T Pham","year":"2004","unstructured":"Pham T, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthr Cartil. 2004;12(5):389\u201399.","journal-title":"Osteoarthr Cartil"},{"issue":"7","key":"6715_CR42","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1136\/annrheumdis-2012-201691","volume":"72","author":"DA Dore","year":"2013","unstructured":"Dore DA, et al. The association between objectively measured physical activity and knee structural change using MRI. Ann Rheum Dis. 2013;72(7):1170\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"6715_CR43","doi-asserted-by":"publisher","first-page":"R222","DOI":"10.1186\/ar3209","volume":"12","author":"D Dore","year":"2010","unstructured":"Dore D, et al. Bone marrow lesions predict site-specific cartilage defect development and volume loss: a prospective study in older adults. Arthritis Res Ther. 2010;12(6):R222.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"6715_CR44","doi-asserted-by":"publisher","first-page":"R21","DOI":"10.1186\/ar1875","volume":"8","author":"JP Raynauld","year":"2006","unstructured":"Raynauld JP, et al. Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. Arthritis Res Ther. 2006;8(1):R21.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"6715_CR45","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.joca.2012.07.019","volume":"20","author":"LL Laslett","year":"2012","unstructured":"Laslett LL, et al. Treatment with 4Jointz reduces knee pain over 12 weeks of treatment in patients with clinical knee osteoarthritis: a randomised controlled trial. Osteoarthr Cartil. 2012;20(11):1209\u201316.","journal-title":"Osteoarthr Cartil"},{"issue":"11","key":"6715_CR46","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1002\/1529-0131(200011)43:11<2543::AID-ANR23>3.0.CO;2-K","volume":"43","author":"G Jones","year":"2000","unstructured":"Jones G, et al. Sex and site differences in cartilage development: a possible explanation for variations in knee osteoarthritis in later life. Arthritis Rheum. 2000;43(11):2543\u20139.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"6715_CR47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1023\/A:1008815005736","volume":"8","author":"G Hawthorne","year":"1999","unstructured":"Hawthorne G, Richardson J, Osborne R. The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health-related quality of life. Qual Life Res. 1999;8(3):209\u201324.","journal-title":"Qual Life Res"},{"issue":"10","key":"6715_CR48","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"issue":"4","key":"6715_CR49","first-page":"685","volume":"3","author":"JK Lee","year":"2007","unstructured":"Lee JK, et al. How should we measure medication adherence in clinical trials and practice? Ther Clin Risk Manag. 2007;3(4):685\u201390 PMID: 18472991.","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"6715_CR50","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/art.20108","volume":"50","author":"G Zhai","year":"2004","unstructured":"Zhai G, et al. The genetic contribution to muscle strength, knee pain, cartilage volume, bone size, and radiographic osteoarthritis: a sibpair study. Arthritis Rheum. 2004;50(3):805\u201310.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"6715_CR51","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1185\/030079906X132488","volume":"22","author":"R Freynhagen","year":"2006","unstructured":"Freynhagen R, et al. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22(10):1911\u201320.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"6715_CR52","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606\u201313.","journal-title":"J Gen Intern Med"},{"issue":"4","key":"6715_CR53","doi-asserted-by":"publisher","first-page":"R120","DOI":"10.1186\/ar2783","volume":"11","author":"RM Bennett","year":"2009","unstructured":"Bennett RM, et al. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther. 2009;11(4):R120.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"6715_CR54","doi-asserted-by":"publisher","first-page":"R58","DOI":"10.1186\/ar3311","volume":"13","author":"R Friend","year":"2011","unstructured":"Friend R, Bennett RM. Distinguishing fibromyalgia from rheumatoid arthritis and systemic lupus in clinical questionnaires: an analysis of the revised Fibromyalgia Impact Questionnaire (FIQR) and its variant, the Symptom Impact Questionnaire (SIQR), along with pain locations. Arthritis Res Ther. 2011;13(2):R58.","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"6715_CR55","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1001\/jama.2016.1961","volume":"315","author":"X Jin","year":"2016","unstructured":"Jin X, et al. Effect of Vitamin D Supplementation on Tibial Cartilage Volume and Knee Pain Among Patients With Symptomatic Knee Osteoarthritis: A Randomized Clinical Trial. JAMA. 2016;315(10):1005\u201313.","journal-title":"JAMA"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06715-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06715-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06715-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T17:02:48Z","timestamp":1662915768000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06715-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,11]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6715"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06715-w","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,11]]},"assertion":[{"value":"1 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval has been obtained from the Tasmania Health and Medical Human Research Ethics Committee (H0017151), Monash University Human Research Ethics Committee (17684), Alfred Hospital Ethics Committee (427\/18), and South Metropolitan Health Service Human Research Ethics Committee (RGS0000000957). Written informed consent or eConsent (through an online survey issued using REDCap) will be obtained from all patients by a medical doctor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"768"}}